logo2020B taglinecrop

124 Byte Drive, Frederick, MD 21702
Contact Us Form

"Reforming Healthcare by preventing diseases through next generation vaccines”.

Dr. Gregory J. Tobin, President, CEO, Director


President and CEO. Dr. Tobin has led research and technical programs at BMI since 1999.  A vaccinologist and molecular biologist, Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; and coordination of multi-site studies.  Dr. Tobin fosters a highly interactive research and development group to apply the Company’s two proprietary technologies (Novel Inactivated Vaccines and Immune Refocusing Technology) to the design of improved vaccines. 

Current research projects employ the technology used in UltraIPV to the derivation of vaccines against two antibiotic-resistant bacteria, Acinetobacter baumannii and MRSA. In addition, Dr. Tobin’s work includes the use of Immune Refocusing in the design of the first vaccine against human rhinovirus (HRV) and of a broadly protective influenza vaccine.  Dr. Tobin has been the Principal Investigator or technical lead on twelve NIH grants, seven DOD research contracts, and several grants funded by other agencies or companies.

 Selected Published Works of Gregory J. Tobin, PhD.

Dr. David S. Silberstein, Director, Scientific Advisor

Dave cropframeDirector and Scientific Advisor. Dr. Silberstein received his PhD in Microbiology at Columbia University and Postdoctoral training at Harvard Med School/Brigham & Women’s Hospital.  He continued for seven years with a faculty appointment at Harvard, leading an NIH-funded research team studying the biochemistry of lung inflammation. 

This was followed by 20 years at AstraZeneca Pharmaceuticals where he had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. Since 2013, he has worked as an advisor and company officer with a number of early stage biotech companies and as a consultant to investment firms.

Mr. Barry Henderson, M.Sc., Director of Business Development.

barryDirector of Business Development. Barry holds a M.Sc. in Bacteriology & Virology and M.Sc. Molecular Pathology both from University of Manchester. He has over 20 years business development experience working with academics, businesses and clinicians to develop and progress innovative technologies to market.

He recently completed a three-year contract as Business Development Director, leading the Life Sciences sector with Invest NI’s US Office, and brings a wealth of relevant experience, having previously held roles in biomedical research, sales & marketing within the biotech sector and life science innovation management with Ulster University.

Mr. A Gregory Kelly, MS, MBA, CPA, Chairman of the Board

Greg Kellycrop

Chair, Board of Directors. Greg Kelly, M.S., M.B.A., has been an active member of Maryland’s emerging business community for over 35 years. He has invested in a number of early-stage companies, and he has founded, been a Board Member of, or been a strategic advisor and financial consultant to numerous other companies.

For 20 years, Greg served in the Health Care & Life Sciences practice of KPMG in Baltimore, where he managed or provided public and private offerings assistance, financial structuring advice , transactions services, small and large company performance improvement initiatives, and attestation services.

Greg is currently a founder, the Co-President, the Chief Science Officer and the Chief Financial Officer of Blue Ocean Biosystems, Inc. in Easton, Maryland, and the Managing Director of Acadine Ventures, LLC.

Dr. Peter L. Nara, Chairman Emeritus

PaterNaraDr. Nara is a co-founder and former President, Chairman and CEO (1997-2017) of Biological Mimetics, Inc. Dr. Nara holds an M.Sc. in Immuno-pharmacology and a combined DVM and Ph.D. from The Ohio State University.

Dr. Nara is a distinguished Alumnus of The Ohio State University College of Veterinary Medicine (2014) and a Fellow of the American Association for the Advancement of Science (2011). His research interests include the development of protective long-lasting responses against infectious pathogens and cancer together with technologies to circumvent non-protective immune responses. 

Dr. Nara currently serves as the Chief Scientific Officer of Keystone Bio, Inc., a company co-founded by BMI to develop antibodies effective against cardiac disease and Alzheimer’s Disease    http://keystonebio.com


For further information, please use our Contact Us Form

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.